News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Foundation Medicine, Inc. (FMI) Discovers High Incidence of Clinically Actionable ERBB2 (HER2) Alterations In Aggressive Form Of Bladder Cancer; Data Published In Clinical Cancer Research


1/9/2014 8:40:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced the discovery of a high incidence of ERBB2 (HER2) extracellular domain alterations in patients with micropapillary urothelial carcinoma (MPUC), a particularly aggressive form of urinary bladder cancer, using FoundationOneā„¢. The research was published in the current edition of Clinical Cancer Research1.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES